William Chuk Kit Ng

William Chuk Kit Ng

Auto-generated profile, based on publicly available information

William Chuk Kit Ng

University of Toronto

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2015 in Anaesthesiology Intensive Therapy
Verified
Journal Article
Open access
PDF file
WNWilliam Chuk Kit Ng
William Chuk Kit Ng
AJAngela Jerath
Angela Jerath
MWMarcin Wasowicz
Marcin Wasowicz
Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings. Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings.

1 May 2020 in Critical Care Explorations
Verified
Journal Article
Open access
JHJay S. Md Han
Jay S. Md Han
AMAzad Mashari
Azad Mashari
DSDevin Singh
Devin Singh
JDJose Dianti
Jose Dianti
EGEwan Goligher
Ewan Goligher
ASArthur S. Slutsky
Arthur S. Slutsky
Objectives: To design and test a ventilator circuit that can be used for ventilation of two or more patients with a single ventilator, while allowing individualization of tidal volume, fractional concentration of oxygen, and positive end-expiratory pressure to each patient, irrespective of the other patient’s respiratory system mechanics. Design: Description and proof of concept studies. Settings: Respiratory therapy laboratory. Subjects: Ventilation of mechanical test lungs. Interventions: Following a previously advocated design, we used components readily available in our hospital to assemble two “bag-in-a-box” breathing circuits. Each patient circuit consisted of a flexible bag in a rigid container connected via one-way valve to a test lung, along with an inline positive end-expiratory pressure valve, connected to the ventilator’s expiratory limb. Compressed gas fills the bags during “patient” exhalation. During inspiration, gas from the ventilator, in pressure control mode, enters the containers and displaces gas from the bags to the test lungs. We varied tidal volume, “respiratory system” compliance, and positive end-expiratory pressure in one lung and observed the effect on the tidal volume of the other. Measurements and Main Results: We were able to obtain different tidal volume, dynamic driving pressure, and positive end-expiratory pressure in the two lungs under widely different compliances in both lungs. Complete obstruction, or disconnection at the circuit connection to one test lung, had minimal effect (< 5% on average) on the ventilation to the co-ventilated lung. Conclusions: A secondary circuit “bag-in-the-box” system enables individualized ventilation of two lungs overcoming many of the concerns of ventilating more than one patient with a single ventilator.

1 September 2020 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
DFDavid Faraoni
David Faraoni
WNWilliam C.K. Ng
William C.K. Ng

13 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WNWilliam C. K. Ng
William C. K. Ng
AHArnaud Romeo Mbadjeu Hondjeu
Arnaud Romeo Mbadjeu Hondjeu
ASAndrew Syrett
Andrew Syrett
RCRebecca Caragata
Rebecca Caragata
DRDmitry Rozenberg
Dmitry Rozenberg
AMAzad Mashari
Azad Mashari
Introduction: The COVID-19 pandemic has unveiled widespread shortages of personal protective equipment including N95 respirators. Several centers are developing reusable stop-gap respirators as alternatives to disposable N95 respirators during public health emergencies, using techniques such as 3D-printing, silicone moulding and plastic extrusion. Effective sealing of the mask, combined with respiratory filters should achieve 95% or greater filtration of particles less than 1um. Quantitative fit-testing (QNFT) data from these stop-gap devices has not been published to date. Our team developed one such device, the “SSM”, and evaluated it using QNFT. Methods: Device prototypes were iteratively evaluated for comfort, breathability and communication, by team members wearing them for 15-30min. The fit and seal were assessed by positive and negative pressure user seal checks. The final design was then formally tested by QNFT, according to CSA standard Z94.4–18 in 40 volunteer healthcare providers. An overall fit-factor >100 is the passing threshold. Volunteers were also tested by QNFT on disposable N95 masks which had passed qualitative fit testing (QLFT) by institutional Occupational Health and Safety Department. Results: The SSM scored 3.5/5 and 4/5 for comfort and breathability. The median overall harmonic mean fit-factors of disposable N95 and SSM were 137.9 and 6316.7 respectively. SSM scored significantly higher than disposable respirators in fit-test runs and overall fit-factors (p <0.0001). Overall passing rates in disposable and SSM respirators on QNFT were 65% and 100%. During dynamic runs, passing rates in disposable and SSM respirators were 68.1% and 99.4%; harmonic means were 73.7 and 1643. Conclusions: We present the design and validation of a reusable N95 stop-gap filtering facepiece respirator that can match existent commercial respirators. This sets a precedence for adoption of novel stop-gap N95 respirators in emergency situations.

17 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VAVahid Anwari
Vahid Anwari
WNWilliam C. K. Ng
William C. K. Ng
AHArnaud Romeo Mbadjeu Hondjeu
Arnaud Romeo Mbadjeu Hondjeu
ZXZixuan Xiao
Zixuan Xiao
EAEdem Afenu
Edem Afenu
AMAzad Mashari
Azad Mashari
Introduction: The COVID-19 pandemic has led to widespread shortages of N95 respirators and other personal protective equipment (PPE). An effective, reusable, locally-manufactured respirator can mitigate this problem. We describe the development, manufacture, and preliminary testing of an open-hardware-licensed device, the “simple silicone mask” (SSM). Methods: A multidisciplinary team developed a reusable silicone half facepiece respirator over 9 prototype iterations. The manufacturing process consisted of 3D printing and silicone casting. Prototypes were assessed for comfort and breathability. Filtration was assessed by user seal checks and quantitative fit-testing according to CSA Z94.4–18. Results: The respirator originally included a cartridge for holding filter material; this was modified to connect to standard heat-moisture exchange (HME) filters (N95 or greater) after the cartridge showed poor filtration performance due to flow acceleration around the filter edges, which was exacerbated by high filter resistance. All 8 HME-based iterations provided an adequate seal by user seal checks and achieved a pass rate of 87.5% (N = 8) on quantitative testing, with all failures occurring in the first iteration. The overall median fit-factor was 1662 (100 = pass). Estimated unit cost for a production run of 1000 using distributed manufacturing techniques is CAD $15 in materials and 20 minutes of labor. Conclusion: Small-scale manufacturing of an effective, reusable N95 respirator during a pandemic is feasible and cost-effective. Required quantities of reusables are more predictable and less vulnerable to supply chain disruption than disposables. With further evaluation, such devices may be an alternative to disposable respirators during public health emergencies. The respirator described above is an investigational device and requires further evaluation and regulatory requirements before clinical deployment. The authors and affiliates do not endorse the use of this device at present.

17 November 2017 in Journal of Anesthesia
Verified
Journal Article
Closed access
PDF file
ASAalap C. Shah
Aalap C. Shah
WNWilliam C. K. Ng
William C. K. Ng
SSSean Sinnott
Sean Sinnott
JCJoesph P Cravero
Joesph P Cravero